Product
Help
Pricing
About
Jobs
Log in
Get started
Institution
Add to collection
Bristol-Myers Squibb (Switzerland)
Homepage:
bms.com
Parent institution:
Bristol-Myers Squibb (United States)
ROR:
02xqc6638
OpenAlex ID:
I47396830
Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study
2022
·
Jeremy S. Abramson
, Scott R. Solomon
, et al.
·
Blood
·
400
PDF
Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study
2022
·
Alison Sehgal
, Daanish Hoda
, et al.
·
The Lancet Oncology
·
242
Romidepsin Plus CHOP Versus CHOP in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Results of the Ro-CHOP Phase III Study (Conducted by LYSA)
2021
·
Emmanuel Bachy
, Vincent Camus
, et al.
·
Journal of Clinical Oncology
·
197
Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial
2021
·
Courtney D DiNardo
, Andre C Schuh
, et al.
·
The Lancet Oncology
·
197
Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma
2023
·
Toni K. Choueiri
, Thomas Powles
, et al.
·
New England Journal of Medicine
·
164
PDF
Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study
2024
·
Franck Morschhauser
, Saurabh Dahiya
, et al.
·
Nature Medicine
·
151
PDF
Adjuvant nab -Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial
2022
·
Margaret A. Tempero
, Uwe Pelzer
, et al.
·
Journal of Clinical Oncology
·
143
PDF
Directed Migration of Cortical Interneurons Depends on the Cell-Autonomous Action of Sip1
2013
·
Veronique van den Berghe
, Elke Stappers
, et al.
·
Neuron
·
120
PDF
Real-World Evidence for Regulatory Decision-Making: Guidance From Around the World
2022
·
Leah Burns
, Nadege Le Roux
, et al.
·
Clinical Therapeutics
·
105
Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma
2023
·
Paul G. Richardson
, Suzanne Trudel
, et al.
·
New England Journal of Medicine
·
102
PDF
Nivolumab for relapsed/refractory classical Hodgkin lymphoma: 5-year survival from the pivotal phase 2 CheckMate 205 study
2023
·
Stephen M. Ansell
, Paul J. Bröckelmann
, et al.
·
Blood Advances
·
96
PDF
Lisocabtagene Maraleucel (liso-cel), a CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy, Versus Standard of Care (SOC) with Salvage Chemotherapy (CT) Followed By Autologous Stem Cell Transplantation (ASCT) As Second-Line (2L) Treatment in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Randomized Phase 3 Transform Study
2021
·
Manali Kamdar
, Scott R. Solomon
, et al.
·
Blood
·
90
Phase III, Randomized, Placebo-Controlled Trial of CC-486 (Oral Azacitidine) in Patients With Lower-Risk Myelodysplastic Syndromes
2021
·
Guillermo Garcia-Manero
, Valeria Santini
, et al.
·
Journal of Clinical Oncology
·
79
Ide-cel vs standard regimens in triple-class–exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses
2024
·
Sikander Ailawadhi
, Bertrand Arnulf
, et al.
·
Blood
·
78
Oral azacitidine prolongs survival of patients with AML in remission independently of measurable residual disease status
2022
·
Gail J. Roboz
, Farhad Ravandi
, et al.
·
Blood
·
65
Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse
2020
·
Meletios Dimopoulos
, Katja Weisel
, et al.
·
Leukemia
·
64
PDF
First-Line Nivolumab and Relatlimab Plus Chemotherapy for Gastric or Gastroesophageal Junction Adenocarcinoma: The Phase II RELATIVITY-060 Study
2024
·
Susanna Hegewisch-Becker
, Guillermo Mendez
, et al.
·
Journal of Clinical Oncology
·
62
Safety and efficacy of luspatercept for the treatment of anemia in patients with myelofibrosis
2024
·
Aaron T. Gerds
, Claire Harrison
, et al.
·
Blood Advances
·
46
Neoadjuvant nivolumab + palbociclib + anastrozole for oestrogen receptor-positive/human epidermal growth factor receptor 2-negative primary breast cancer: Results from CheckMate 7A8
2023
·
Guy Jerusalem
, Aleix Prat
, et al.
·
The Breast
·
46
PDF
Real-world evidence for regulatory decision-making: updated guidance from around the world
2023
·
Leah Burns
, Nadege Le Roux
, et al.
·
Frontiers in Medicine
·
44
Lisocabtagene Maraleucel Versus Standard of Care for Second-Line Relapsed/Refractory Large B-Cell Lymphoma: 3-Year Follow-Up From the Randomized, Phase III TRANSFORM Study
2025
·
Manali Kamdar
, Scott R. Solomon
, et al.
·
Journal of Clinical Oncology
·
43
PDF
Health-related quality of life results from the IFM 2009 trial: treatment with lenalidomide, bortezomib, and dexamethasone in transplant-eligible patients with newly diagnosed multiple myeloma
2020
·
Murielle Roussel
, Benjamin Hebraud
, et al.
·
Leukemia & lymphoma/Leukemia and lymphoma
·
41
Luspatercept stimulates erythropoiesis, increases iron utilization, and redistributes body iron in transfusion‐dependent thalassemia
2023
·
Maciej W. Garbowski
, Manuel Ugidos
, et al.
·
American Journal of Hematology
·
37
PDF
Oral azacitidine compared with standard therapy in patients with relapsed or refractory follicular helper T-cell lymphoma (ORACLE): an open-label randomised, phase 3 study
2024
·
Jehan Dupuis
, Emmanuel Bachy
, et al.
·
The Lancet Haematology
·
35
Patient‐reported outcome measures in studies of myelodysplastic syndromes and acute myeloid leukemia: Literature review and landscape analysis
2020
·
Reinhard Stauder
, Jérémy Lambert
, et al.
·
European Journal Of Haematology
·
34
PDF
Show more works
View as search
Works count:
393
Citation count:
7,510
Year
Topic
Type
